Kerydin Side Effects Center

Last updated on RxList: 4/4/2022
Kerydin Side Effects Center

What Is Kerydin?

Kerydin (tavaborole) topical solution is an antifungal used to treat fungal infection (onychomycosis) of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.

What Are Side Effects of Kerydin?

Common side effects of Kerydin include:

  • ingrown toenail,
  • sloughing or peeling of dead skin,
  • skin redness, and
  • skin inflammation at the application site

Dosage for Kerydin

Apply a dose of Kerydin to affected toenails once daily for 48 weeks.

What Drugs, Substances, or Supplements Interact with Kerydin?

Kerydin may interact with other drugs. Tell your doctor all medications and supplements you use.

Kerydin During Pregnancy or Breastfeeding

During pregnancy, Kerydin should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Kerydin (tavaborole) topical solution Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Ringworm is caused by a fungus. See Answer
Kerydin Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • severe redness, swelling, or other irritation of the affected toenail.

Common side effects may include:

  • skin peeling or redness where the medicine was applied;
  • itching; or
  • ingrown toenail.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Kerydin (Tavaborole Topical Solution, 5%)


Rosacea, Acne, Shingles, Covid-19 Rashes: Common Adult Skin Diseases See Slideshow
Kerydin Professional Information


Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two clinical trials, 791 subjects were treated with KERYDIN. The most commonly reported adverse reactions are listed below (Table 1).

Table 1: Adverse Reactions Occurring in ≥1% of KERYDIN Topical Solution, 5%-Treated Subjects and at a Greater Frequency than Observed with Vehicle

Preferred Term KERYDIN
Application site exfoliation 21 (2.7%) 1 (0.3%)
Ingrown toenail 20 (2.5%) 1 (0.3%)
Application site erythema 13 (1.6%) 0 (0%)
Application site dermatitis 10 (1.3%) 0 (0%)

Postmarketing Experience

The following adverse reactions have been identified during postmarketing use of KERYDIN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug product exposure:

Hypersensitivity; contact allergy

Read the entire FDA prescribing information for Kerydin (Tavaborole Topical Solution, 5%)

© Kerydin Patient Information is supplied by Cerner Multum, Inc. and Kerydin Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors